Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-11-27 9:24 pm Unchanged | 13D | RVL PHARMACEUTICALS PLC RVLPQ | Athyrium Opportunities IV Acquisition 2 LP | 14,600,444 13.100% | 0 (Unchanged) | View |
| 2023-11-01 4:27 pm Sale | 13D | RVL PHARMACEUTICALS PLC RVLPQ | Altchem Ltd | 1,182,243 1.100% | -22,485,297 (-95.00%) | View |
| 2023-10-13 5:28 pm Unchanged | 13D | RVL PHARMACEUTICALS PLC RVLPQ | Athyrium Opportunities IV Acquisition 2 LP | 14,600,444 13.100% | 0 (Unchanged) | View |
| 2023-09-05 07:45 am Unchanged | 13D | RVL PHARMACEUTICALS PLC RVLPQ | Athyrium Opportunities IV Acquisition 2 LP | 14,600,444 13.100% | 0 (Unchanged) | View |
| 2023-08-17 5:06 pm Sale | 13D | RVL PHARMACEUTICALS PLC RVLPQ | Avista Healthcare Partners GP Ltd. | 0 0.000% | -23,730,864 (Position Closed) | View |
| 2023-01-30 5:23 pm Purchase | 13D | RVL PHARMACEUTICALS PLC RVLPQ | Avista Healthcare Partners GP Ltd. | 23,730,864 23.900% | 23,730,864 (New Position) | View |
| 2022-08-11 3:53 pm Purchase | 13G | RVL PHARMACEUTICALS PLC RVLPQ | Athyrium Opportunities IV Acquisition 2 LP | 14,600,444 14.750% | 6,262,242 (+75.10%) | View |
| 2022-08-09 5:20 pm Purchase | 13D | RVL PHARMACEUTICALS PLC RVLPQ | Avista Capital Partners III GP L.P. | 23,730,864 24.000% | 8,000,000 (+50.86%) | View |
| 2021-11-03 4:30 pm Unchanged | 13D | RVL PHARMACEUTICALS PLC RVLPQ | Altchem Ltd | 23,667,540 28.400% | 0 (Unchanged) | View |
| 2021-10-22 4:27 pm Purchase | 13G | RVL PHARMACEUTICALS PLC RVLPQ | Athyrium Opportunities IV Acquisition 2 LP | 8,338,202 9.990% | 8,338,202 (New Position) | View |
| 2021-10-14 4:10 pm Unchanged | 13D | RVL PHARMACEUTICALS PLC RVLPQ | Avista Capital Partners III GP L.P. | 15,730,864 18.900% | 0 (Unchanged) | View |
| 2021-04-29 4:49 pm Sale | 13G | RVL PHARMACEUTICALS PLC RVLPQ | Orbit Co-Invest I LLC | 0 0.000% | -4,936,926 (Position Closed) | View |
| 2020-11-25 7:01 pm Purchase | 13G | RVL PHARMACEUTICALS PLC RVLPQ | Orbit Co-Invest I LLC | 4,936,926 7.900% | 4,936,926 (New Position) | View |
| 2020-11-23 4:53 pm Unchanged | 13D | RVL PHARMACEUTICALS PLC RVLPQ | Avista Capital Partners III GP L.P. | 15,730,864 25.200% | 0 (Unchanged) | View |
| 2020-01-23 4:26 pm Sale | 13D | RVL PHARMACEUTICALS PLC RVLPQ | Avista Capital Partners III GP L.P. | 15,730,864 26.800% | -4,719,921 (-23.08%) | View |
| 2020-01-21 6:24 pm Purchase | 13D | RVL PHARMACEUTICALS PLC RVLPQ | Altchem Ltd | 23,667,540 40.200% | 1,250,000 (+5.58%) | View |